These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 29844385)

  • 21. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L; Sun J; Chen X; Liu L; Wu D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
    Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
    Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.
    Li D; Yao Y; Rao Y; Huang X; Wei L; You Z; Zheng G; Hou X; Su Y; Varghese Z; Moorhead JF; Chen Y; Ruan XZ
    J Exp Clin Cancer Res; 2022 Mar; 41(1):116. PubMed ID: 35354475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma.
    Liang C; Dong Z; Cai X; Shen J; Xu Y; Zhang M; Li H; Yu W; Chen W
    Cell Death Dis; 2020 Nov; 11(11):1017. PubMed ID: 33250518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCC.
    Mo C; You W; Rao Y; Lin Z; Wang S; He T; Shen H; Li X; Zhang R; Li B
    Cell Mol Life Sci; 2024 Jul; 81(1):284. PubMed ID: 38967794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.
    Zheng SS; Wu JF; Wu WX; Hu JW; Zhang D; Huang C; Zhang BH
    Hepatol Int; 2024 Oct; 18(5):1499-1515. PubMed ID: 38769286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
    Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma.
    Dai J; Huang Q; Niu K; Wang B; Li Y; Dai C; Chen Z; Tao K; Dai J
    Cancer Med; 2018 Nov; 7(11):5691-5703. PubMed ID: 30311444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.
    Xu QG; Yu J; Guo XG; Hou GJ; Yuan SX; Yang Y; Yang Y; Liu H; Pan ZY; Yang F; Gu FM; Zhou WP
    Mol Oncol; 2018 Jun; 12(6):936-952. PubMed ID: 29689643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
    Jing W; Shuo L; Yingru X; Min M; Runpeng Z; Jun X; Dong H
    Biochem Biophys Res Commun; 2019 Oct; 519(1):41-45. PubMed ID: 31481232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
    Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
    Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
    Ling S; Song L; Fan N; Feng T; Liu L; Yang X; Wang M; Li Y; Tian Y; Zhao F; Liu Y; Huang Q; Hou Z; Xu F; Shi L; Li Y
    Int J Oncol; 2017 Jan; 50(1):297-309. PubMed ID: 27959383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma.
    Pang L; Xu L; Yuan C; Li X; Zhang X; Wang W; Guo X; Ouyang Y; Qiao L; Wang Z; Liu K
    Mol Carcinog; 2019 Nov; 58(11):2118-2126. PubMed ID: 31465134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma.
    Liu J; Qiu WC; Shen XY; Sun GC
    Math Biosci Eng; 2019 Jul; 16(6):6319-6334. PubMed ID: 31698564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.